{"prompt": "['Alliance A221504', '9.3.1 Expedited Reporting Requirements for Adverse Events that Occur on Studies under', 'an IND/IDE 30 Days of the Last Administration of the Investigational', 'Agent/Intervention', '1', 'FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312)', 'NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events,', 'whether or not they are considered related to the investigational agent(s)/intervention (21 CFR', '312.64)', 'An adverse event is considered serious if it results in ANY of the following outcomes:', '1) Death', '2) A life-threatening adverse event', '3)', 'An adverse event that results in inpatient hospitalization or prolongation of existing hospitalization', 'for > 24 hours', '4)', 'A persistent or significant incapacity or substantial disruption of the ability to conduct normal life', 'functions', '5)', 'A congenital anomaly/birth defect.', '6) Important Medical Events (IME) that may not result in death, be life threatening, or require', 'hospitalization may be considered serious when, based upon medical judgment, they may jeopardize', 'the patient or subject and may require medical or surgical intervention to prevent one of the', 'outcomes listed in this definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6).', 'ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the', 'NCI via CTEP-AERS within the timeframes detailed in the table below.', 'Grade 1', 'Grade 2', 'Grade 3', 'Grade 4 & 5', 'Hospitalization', 'Timeframes', 'Timeframes', 'Timeframes', 'Timeframes', 'Resulting in', 'Hospitalization > 24 hrs', '10 Calendar Days', '24-Hour;', 'Not resulting in', '5 Calendar Days', 'Hospitalization > 24 hrs', 'Not required', '10 Calendar Days', 'NOTE Protocol specific exceptions to expedited reporting of serious adverse events are found in', 'the Specific Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR', 'Expedited AE reporting timelines are defined as:', '\"24-Hour; 5 Calendar Days\" - The AE must initially be reported via CTEP-AERS < 24 hours', 'of learning of the AE, followed by a complete expedited report < 5 calendar days of the', 'initial 24-hour report.', '\"10 Calendar Days\" - A complete expedited report on the AE must be submitted VI 10', 'calendar days of learning of the AE.', '1', 'Serious adverse events that occur more than 30 days after the last administration of investigational', 'agent/intervention and have an attribution of possible, probable, or definite require reporting as', 'follows:', 'Expedited 24-hour notification followed by complete report < 5 calendar days for:', 'All Grade 4, and Grade 5 AEs', 'Expedited 10 calendar day reports for:', 'Grade 2 adverse events resulting in hospitalization or prolongation of hospitalization', 'Grade 3 adverse events', '38', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', 'Expedited AE reporting timelines defined:', '\"24 hours; 5 calendar days\" - The investigator must initially report the AE via CTEP-AERS', '<24 hours of learning of the event followed by a complete CTEP-AERS report 5 calendar', 'days of the initial 24-hour report.', '\"10 calendar days\" - A complete CTEP-AERS report on the AE must be submitted 10', 'calendar days of the investigator learning of the event.', 'Any medical event equivalent to CTCAE grade 3, 4, or 5 that precipitates hospitalization (or', 'prolongation of existing hospitalization) must be reported regardless of attribution and', 'designation as expected or unexpected with the exception of any events identified as protocol-', 'specific expedited adverse event reporting exclusions (see below).', 'Any event that results in persistent or significant disabilities/incapacities, congenital anomalies,', 'or birth defects must be reported via CTEP-AERS if the event occurs following treatment with', 'an agent under a CTEP IND.', 'Use the NCI protocol number and the protocol-specific patient ID provided during trial', 'registration on all reports.', 'Additional Instructions or Exclusion to CTEP-AERS Expedited Reporting Requirements', 'All adverse events reported via CTEP-AERS (i.e., serious adverse events) should also be', 'forwarded to your local IRB.', 'Grade 3/4 hematosuppression and hospitalization resulting from such do not require CTEP-', 'AERS, but should be submitted as part of study results. All other grade 3, 4, or 5 adverse events', 'that precipitate hospitalization or prolong an existing hospitalization must be reported via CTEP-', 'AERS.', 'Reporting of cases of secondary AML/MDS is to be done using the NCI/CTEP Secondary', 'AML/MDS Report Form. New primary malignancies should be reported using Form Notice of', 'New Primary.', 'Death due to progressive disease should be reported as Grade 5 \"Disease progression\" in the', 'system organ class (SOC) \"General disorders and administration site conditions.\" Evidence that', 'the death was a manifestation of underlying disease (e.g., radiological changes suggesting tumor', 'growth or progression: clinical deterioration associated with a disease process) should be', 'submitted.', 'All new malignancies must be reported via CTEP-AERS whether or not they are thought to be', 'related to either previous or current treatment. All new malignancies should be reported, i.e. solid', 'tumors (including non-melanoma skin malignancies), hematologic malignancies,', 'myelodysplastic syndrome/acute myelogenous leukemia, and in situ tumors.', 'Secondary Malignancy:', 'A secondary malignancy is a cancer caused by treatment for a previous malignancy (e.g., treatment', 'with investigational agent/intervention, radiation or chemotherapy). A secondary malignancy is not', 'considered a metastasis of the initial neoplasm.', 'CTEP requires all secondary malignancies that occur following treatment with an agent under an NCI', 'IND/IDE be reported via CTEP-AERS. Three options are available to describe the event:', 'Leukemia secondary to oncology chemotherapy (e.g., acute myelocytic leukemia [AML])', 'Myelodysplastic syndrome (MDS)', 'Treatment-related secondary malignancy', 'Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported', 'via the routine reporting mechanisms outlined in each protocol.', '39', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}